Publications

trends of respiratory syncytial virus infections in children under 2 years of age in puerto rico.	the respiratory syncytial virus (rsv) is the most significant viral pathogen causing bronchiolitis and pneumonia in infants, today. in tropical climates the rsv infection may occur throughout the year. the purpose of this study was to asses rsv infections during the 2009‒2010 rsv season in children under 2 years of age and to evaluate the trend of positive rsv tests in the period of 2007 to 2009.	2015	26061061
palivizumab compliance by infants in puerto rico during the 2009-2010 respiratory syncytial virus season.	respiratory syncytial virus (rsv) is the leading viral pathogen responsible for bronchiolitis and pneumonia in infants. we assessed palivizumab prophylaxis compliance for infants in puerto rico. we retrospectively studied data from 868 infants (409 females, 459 males) during the 2009-2010 rsv season. the infants had a mean gestational age of 33 weeks (range 23-41) and a mean birth weight of 1,767 g (range 509-4,120). only 74 % of the infants with indications received prophylaxis. the main reason ...	2014	24756837
antiviral research--19th international conference. 7-11 may 2006, san juan, puerto rico.		2006	16821155
respiratory syncytial virus-related bronchiolitis in puerto rico.	respiratory syncytial virus (rsv) is an important cause of respiratory tract disease in infants and young children. immunoprophylaxis is available for high-risk infants. this study reviews infants with bronchiolitis at three primary care hospitals to describe the epidemiology of rsv infection in puerto rico.	2005	16116931
prevention of respiratory syncytial virus infection among puerto rican infants.	respiratory syncytial virus (rsv) is the leading cause of lower respiratory illness in children. prevention of this infection is available with the use of intravenous immunoglobulin or an intramuscular humanized monoclonal antibody (palivizumab). palivizumab has been available in puerto rico since 1999. the objective of this study was to follow-up infants who received rsv prophylaxis with palivizumab in puerto rico to assess its efficacy and safety. a total of 230 infants who received rsv prophy ...	2002	12243108